Telegraph Hill Partners

The firm focuses on commercial-stage companies with existing revenues and a demonstrated customer base, spanning growth equity and management buyouts. It is typically the first institutional investor in bootstrapped businesses and also structures founder liquidity transactions. Additionally, it executes corporate carve-outs, acquiring divisions from larger companies to operate them independently.

Telegraph Hill Partners concentrates exclusively on the life science and healthcare sectors, specifically discovery tools, automation, diagnostics, healthcare IT, and medical devices. The firm does not pursue therapeutic drug development, consumer health apps, or health services businesses outside its defined infrastructure focus. Its portfolio and public statements contain no evidence of activity outside these sub-sectors.

All publicly available information describes direct investment activity — growth equity rounds, management buyouts, and founder liquidity deals — with no mention of fund-of-fund commitments or allocations to external managers. The firm's strategy page emphasizes being the lead or sole institutional investor, reinforcing a direct-only approach.

Sourcing relies on deep domain relationships within the life science tools, diagnostics, and device communities, often engaging companies that have bootstrapped to profitability without prior venture backing. The firm's public posture — inviting companies with revenues and solid customer bases to reach out directly — suggests a relationship-driven origination model rather than a broad auction-based process. Its ability to execute corporate carve-outs also provides access to deals that are structurally invisible to pure venture or pure buyout funds.

The firm occupies a hybrid position: it writes equity checks into revenue-stage companies, resembling growth equity, but also pursues management buyouts and corporate carve-outs, which are hallmarks of traditional private equity. This dual capability, confined to a single sector vertical, differentiates it from both generalist venture firms and multi-sector mid-market buyout funds.